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A B S T R A C T
Purpose
The clinical efficacy of tamoxifen is suspected to be influenced by the activity of drug-metabolizing
enzymes and transporters involved in the formation, metabolism, and elimination of its active
forms. We investigated relationships of polymorphisms in transporter genes and CYP2D6 to
clinical outcome of patients receiving tamoxifen.
Patients and Methods
We studied 282 patients with hormone receptor–positive, invasive breast cancer receiving tamoxifen
monotherapy, including 67 patients who have been previously reported. We investigated the effects
of allelic variants of CYP2D6 and haplotype-tagging single nucleotide polymorphisms (tag-SNPs) of
ABCB1, ABCC2, and ABCG2 on recurrence-free survival using the Kaplan-Meier method and Cox
regression analysis. Plasma concentrations of tamoxifen metabolites were measured in 98 patients
receiving tamoxifen 20 mg/d.
Results
CYP2D6 variants were significantly associated with shorter recurrence-free survival (P  .000036;
hazard ratio [HR]  9.52; 95% CI, 2.79 to 32.45 in patients with two variant alleles v patients
without variant alleles). Among 51 tag-SNPs in transporter genes, a significant association was
found at rs3740065 in ABCC2 (P  .00017; HR  10.64; 95% CI, 1.44 to 78.88 in patients with
AA v GG genotypes). The number of risk alleles of CYP2D6 and ABCC2 showed cumulative effects
on recurrence-free survival (P  .000000055). Patients carrying four risk alleles had 45.25-fold
higher risk compared with patients with  one risk allele. CYP2D6 variants were associated with
lower plasma levels of endoxifen and 4-hydroxytamoxifen (P .0000043 and .00052), whereas no
significant difference was found among ABCC2 genotype groups.
Conclusion
Our results suggest that polymorphisms in CYP2D6 and ABCC2 are important predictors for the
prognosis of patients with breast cancer treated with tamoxifen.
J Clin Oncol 28:1287-1293. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Tamoxifen has beenwidely used for the treatment
and prevention of recurrence in patients with es-
trogen receptor (ER)–positive or progesterone
receptor (PR)–positive breast cancers. However,
30% to 50% of patients who receive adjuvant
tamoxifen therapy experience relapse and subse-
quently die of the disease.1,2 Despite decades of
research, the mechanisms underlying the inef-
fectiveness in a subset of the patients are not
fully understood.
Tamoxifen is aprodrug that requiresmetabolic
activation to elicit its pharmacologic activity. It is
reported that its metabolites, 4-hydroxytamoxifen
and 4-hydroxy-N-desmethyltamoxifen (endoxifen),
are the active therapeutic moieties.3-5 Compared
with the parent drug, these two metabolites have
100-fold greater affinity to ER and 30- to 100-fold
greater potency in suppressing estrogen-dependent
cell proliferation.3-5 Thus, interindividual differ-
ences in the formation and elimination of these ac-
tive metabolites could be one of the important
factors affectingvariability in response to tamoxifen.
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CYP2D6 is a key enzyme for the generation of 4-hydroxytamoxifen
and endoxifen.6 Several groups including ours have clarified that loss
or decrease of CYP2D6 function by genetic polymorphisms is associ-
atedwith poorer clinical outcome of tamoxifen treatment in different
populations.7-10Althoughgenetic polymorphisms inCYP2D6 areone
of themost important determinants for clinical efficacy of tamoxifen,
individual differences in responsiveness to tamoxifen still remain,
even if the effects of CYP2D6 polymorphisms are considered, sug-
gesting the existence of another genetic factor(s) contributing to
individual differences in the formation and elimination of the active
metabolites of tamoxifen. However, no large-scale clinical trial exists
that investigates the relationship of polymorphisms in tamoxifen
pharmacokinetics (PK) -related genes, including CYP2D6, to clinical
efficacy of adjuvant tamoxifen therapy. Tamoxifen is primarily elimi-
nated by hepatic oxidative metabolism; approximately 75% of the
dose is excreted into the biliary tract as glucuronides.4 It has been
reported that several transporters expressed in cancer cells play
important roles in resistance to tamoxifen.11-13 Therefore, adenosine
triphosphate–binding cassette (ABC) transporter B1 (ABCB1; also
known as multidrug resistance 1 [MDR1]), ABCC2 (also known as
multidrug resistance-associated protein 2 [MRP2]), andABCG2 (also
known as breast cancer resistance protein [BCRP]), which have been
reported to transport various types of glucuronides or sulfates,14,15
may be involved in the transport of tamoxifen and/or its metabolites,
and their genetic variationsmay influence the individual difference in
tamoxifen efficacy.
In this study,we focusedon threeABC transporters and compre-
hensively analyzed their associations, as well as the association of
CYP2D6,with clinical outcomeafter tamoxifenmonotherapy, using a
larger number of samples. In addition, we investigated the effects of
these polymorphisms on the steady-state plasma concentrations of
tamoxifen and its metabolites in patients with breast cancer receiving
tamoxifen therapy.
PATIENTS AND METHODS
Patients
We had two objectives in this study. The primary objective was to
determine the association between genotype of the tamoxifen PK-related
genes and recurrence-free survival (genotype-efficacy study). The secondary
objective was to determine the association between genotype of the tamoxifen
PK-related genes and plasma concentrations of tamoxifen and its metabolites
(genotype-PK study) in patients with breast cancer receiving tamoxifen ther-
apy. In the genotype-efficacy study, 282 patients with primary breast cancer
(including 67 patients who have been reported previously7) were recruited
from September 2007 to April 2009 at Shikoku-*10 collaborative group (To-
kushimaBreast CareClinic, YamakawaBreast Clinic, ShikokuCancerCenter,
Kochi University Hospital, and Itoh Surgery and Breast Clinic), Kansai Rosai
Hospital, Sapporo Breast Surgical Clinic, and Sapporo Medical University
Hospital.Allpatientswere JapanesewomenpathologicallydiagnosedwithER-
and/orPR-positive, invasivebreast cancerwithoutdistant spreadwhoreceived
adjuvant tamoxifenmonotherapy without any other treatments after surgical
treatment between 1986 and 2007.Data onprimary breast cancer diagnosis or
recurrence were confirmed from the patients’ medical records. Patients with-
out recurrence were censored at the date of the last consultation. Recurrence-
free survival timewas defined as the time from surgical treatment to diagnosis
of the recurrence of a breast cancer (locoregional, distant metastasis, and
contralateral breast events). Patients received tamoxifen 20 mg/d for 5 years;
tamoxifen was stopped at the time a recurrence was identified. ER and PR
statuswas evaluatedby enzyme immunoassayor immunohistochemistry.The
cutoff for human epidermal growth factor receptor 2 overexpression was
defined as 3 immunohistochemical staining.16Nodal statuswas determined
according to the International Union Against Cancer TNM classification. For
the genotype-PK study, 98 independent patients with breast cancer who had
been taking tamoxifen20mgdaily for at least 4weeks (patients taking selective
serotonin reuptake inhibitorswerenot included)were recruitedatTokushima
Breast Care Clinic (Tokushima, Japan). Blood samples (5 mL) were collected
before taking tamoxifen. These studies were approved by the Institutional
Review Board of the Institute of Medical Science, The University of Tokyo
(Tokyo, Japan), andwritten informed consent was obtained from all patients.
Genotyping
GenomicDNAwas extracted fromperipheral blood usingQiagenDNA
extraction kit (Qiagen, Valencia, CA). Genotyping for key polymorphisms for
CYP2D6*4 (1846GA), CYP2D6*6 (1707delT), CYP2D6*10 (100CT),
CYP2D6*14B (1758GA), CYP2D6*18 (4125_4133dupGTGCCCACT),
CYP2D6*21 (2573_2574insC), CYP2D6*36 (gene conversion to CYP2D7 in
exon 9), and CYP2D6*41 (2988GA) was performed using previously de-
signed primers and probes.17 Determination of allelic ratio and copy number
of CYP2D6 gene was performed using ABI PRISM 7900HT (Applied Biosys-
tems, Foster City, CA), as described previously.17,18 To determine the diplo-
types, whole-gene deletion (CYP2D6*5) and duplications (CYP2D6*1-*1,
CYP2D6*10-*10,CYP2D6*10-36, andCYP2D6*36-*36) were detected fol-
lowing reported protocols.19,20 Multiplication alleles, which consisted of
CYP2D6*10 andCYP2D6*36 (ie,CYP2D6*10-*36 andCYP2D6*10-*36-*36),
were defined asCYP2D6*10 because the enzyme encoded byCYP2D6*36 has
been reported to have negligible activity.21 To evaluate the effects of all
CYP2D6alleles tested in this study,wedefinedall decreasedandnull alleles (*4,
*5, *10, *10-*10, *14, *21, *36-*36, and *41) as alleleV and *1 and *1-*1 alleles
as allelewt.
For ABCB1, ABCC2, and ABCG2, we genotyped haplotype-tagging sin-
gle nucleotide polymorphisms (tag-SNPs) selected with an r2 threshold of 0.8
and minor allele frequency of greater than 10% in the HapMap Japanese
population as described in our previous study.22 In addition, we genotyped
the following possible functional polymorphisms: rs2032582 (2677GT/A)
and rs3213619 (129TC) inABCB1 and rs2273697 (1249GA) inABCC2.
A totalof51SNPsweregenotypedusingmultiplexpolymerasechain reaction–
based Invader assay (Third Wave Technologies, Madison, WI) as descri-
bed previously.23
Measurement of Plasma Concentrations of Tamoxifen and
Its Metabolites
Plasma concentrations of tamoxifen and its metabolites, N-
desmethyltamoxifen, 4-hydroxytamoxifen, and endoxifen, were measured
using a high-performance liquid chromatography with time of flight
mass spectrometry (HPLC-TOFMS). Tamoxifen ( 99%), (Z)-4-
hydroxytamoxifen ( 98%), and imipramine, an internal standard (IS), were
purchased from Sigma-Aldrich (St Louis, MO). N-desmethyltamoxifen
( 98%) was obtained from Toronto Research Chemicals (North York, On-
tario, Canada). Endoxifen was used as a mixture of E and Z isomers (25:75)
described previously.6
Pretreatment of plasma sampleswas carried out by protein precipitation
and solidphase extraction.Briefly, 100L IS solution (imipramine200ng/mL
in acetonitrile) was added to 100L plasma. After mixing and centrifugation
(13,000 rpm, 5minutes, 4°C), 950Lof 25mmol/L sodiumcitrate buffer (pH
5.0) was added to the supernatant. The solutions were then purified by solid
phase extraction using BONDELUTE-C18 cartridges (1mL, 100mg; Varian,
Lake Forest, CA) following the method described previously.24
HPLC-TOFMS was equipped with a 1200 series HPLC system and a
G6210Time-of-Flight LC/MS (AgilentTechnologies, SantaClara,CA).Chro-
matographic separations were obtained under gradient conditions using an
XBridge C18 column (150 3mm ID, 3.5mparticle size;Waters,Milford,
MA). The mobile phase was consisted of eluent A (10 mmol/L ammonium
formate) and eluent B (acetonitrile). The gradientwas as follows: 30%B for
2.0 minutes, 0.2 mL/min; 30% B at 2.01minutes, 0.5 mL/min; 30%B at 3.0
minutes, 0.5 mL/min, 90% B at 20 minutes, 0.5 mL/min; and 98% B at 20.01
minutes, 1.2 mL/min. Injection volume was 20 L, and all separations were
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performed at 30°C. The retention times of imipramine (IS), endoxifen,
4-hydroxytamoxifen, N-desmethyltamoxifen, and tamoxifen were 10.68,
12.22, 12.89, 16.29, and 17.39 minutes, respectively. Electrospray ionization-
TOFMSwas conducted in the positive ionmode. The capillary voltagewas set
at 4,000 V. A flow rate and a nebulizer pressure of nitrogen gas (heater tempera-
ture 360°C)weremaintainedat 10L/minand45psig, respectively. InTOFMS,
the fragmenter voltagewas set at 150V.Twomass-to-charge ratio (m/z)values
of imipramine (IS), N-desmethyltamoxifen, tamoxifen, endoxifen, and
4-hydroxytamoxifen were 281.2, 358.2, 372.2, 374.2, and 388.2, respectively.
Standard curves were prepared in the concentration range of 20 to 1,000
ng/mL for tamoxifen and N-desmethyltamoxifen, 3.75 to 187.5 ng/mL for
endoxifen, and 1 to 20 ng/mL for 4-hydroxytamoxifen. The interday and
intradayvariability inprecision(expressedas thecoefficientofvariation) forall
compounds ranged from 0.7% to 6.6% and from 5.5% to 9.5%, respectively;
the average accuracies were between 94.1% and 102.9%.
Statistical Analysis
Recurrence-free survival curves were estimated using the Kaplan-Meier
method. Statistical significance of a relationship between clinical outcome and
genetic polymorphismwas assessedusing the trend log-rank test.Coxpropor-
tional hazards analysis was used to identify significant prognostic clinical
factors and to test for an independent contribution of genetic factors to
recurrence-free survival.Toexaminepotential confounding, agewas treatedas
a continuous variable, tumor size was treated as an ordinal variable, and the
other covariates were treated as categoric variables. Genotypes were analyzed
by assigning an ordinal score to each genotype (1 for homozygous nonrisk
allele, 2 for heterozygous risk allele, and 3 for homozygous risk allele). The
significant subsets of variables in theunivariate analysiswereused inmultivar-
iate analysis. All polymorphisms evaluated in this study were tested for devia-
tion from Hardy-Weinberg equilibrium with the use of a 2 test. Risk alleles
were defined as the alleles associated with shorter recurrence-free survival.
Combination effects were investigated by adding up the number of risk alleles
of CYP2D6 and ABCC2 genes. The differences in plasma concentrations of
tamoxifen and its metabolites among genotypes were evaluated by a Kruskal-
Wallis test. Statistical tests provided two-sidedP values, anda significance level
of P .05 was used. In the screening of transporter genes, we used a signifi-
cance level of P .00098 to adjust multiple testing by the strict Bonferroni’s
correction. Statistical analyseswere carriedoutusingSPSS (version17.0; SPSS,
Chicago, IL) and the R statistic program (http://www.r-project.org/).
RESULTS
Patient Characteristics
To evaluate the effect of tamoxifen on recurrence-free survival,
we recruited 282 Japanese patients receiving adjuvant tamoxifen
monotherapy without any other anticancer treatments in this study.
Table 1 lists the characteristics of these 282 patients who were patho-
logically diagnosed to have an ER- and/or PR-positive, invasive breast
cancer.Theirmedianageat the timeof surgerywas51yearsold(range,
31 to 83 years), and themedian follow-upperiodwas 7.1 years (range,
0.8 to 23.5 years). Among the characteristics listed in Table 1, tumor
size and nodal status showed significant associations with recurrence-
free survival (P .037 and .049, respectively) in theCox proportional
hazards analysis.
Associations Between Genotypes and
Clinical Outcome
We determined CYP2D6 genotypes of these 282 patients (Table
2). The allele frequency of CYP2D6*10, which is considered to have
decreased enzymatic activity and is known to be present at a relatively
high frequency in Asian populations, was 37.2%. The frequencies of
the alleles observed in this study were comparable to those reported
previously.17,20Toevaluate the effects of theCYP2D6 alleles,we exam-
ined all of the decreased and null alleles (*4, *5, *10, *10-*10, *14, *21,
*36-*36, and *41) as allele V and *1 and *1-*1 alleles as allele wt.
Kaplan-Meier estimates indicated that the patients carrying one or
two variant alleles (wt/V orV/V) had significantly shorter recurrence-
free survival compared with patients with homozygous wild-type al-
leles (wt/wt; log-rankP .0002; Fig 1A). InCoxproportional hazards
analysis, the CYP2D6 genotype was an independent indicator of
recurrence-free survival after adjustment of tumor size and nodal
status (trend P .000036, Table 3). The adjusted hazard ratios (HRs)
of patients with wt/V and V/V genotypes, relative to patients with
wt/wt, were 4.44 (95% CI, 1.31 to 15.00) and 9.52 (95% CI, 2.79 to
32.45), respectively.
We also genotyped tag-SNPs in ABC transporter genes, ABCB1,
ABCC2, andABCG2, which are suspected to be involved in the biliary
excretion of tamoxifen or its metabolites (Appendix Table A1, online
only).15 Among 51 SNPs tested, five SNPs inABCC2 showed P .05
by log-rank test for recurrence-free survival. The lowest P value was
observed at rs3740065 inABCC2 (log-rank P .0002, Fig 1B), which
was significant after the adjustment for multiple testing by the strict
Table 1. Patient Demographics and Clinical Characteristics
Demographic or Clinical
Characteristic
No. of Patients
(N  282) %
Age at surgery, years
Median 51
Range 31-83
Menopausal status
Premenopausal 123 43.6
Postmenopausal 149 52.8
Unknown 10 3.6
Tumor size, cm
 2 159 56.4
2.1-5 106 37.6
 5 2 0.7
Unknown 15 5.3
Nodal status
Negative 230 81.6
Positive 48 17.0
Unknown 4 1.4
ER status
Positive 208 73.8
Negative 25 8.9
Unknown 49 17.3
PR status
Positive 195 69.1
Negative 36 12.8
Unknown 51 18.1
HER2
Positive 5 1.8
Negative 97 34.4
Unknown 180 63.8
Events
No event 241 85.5
Locoregional events 9 3.2
Distant metastasis events 22 7.8
Contralateral breast events 10 3.5
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2,
human epidermal growth factor receptor 2.
Score of 3 in immunohistochemistry.
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Bonferroni’s correction. rs11190303 in ABCC2 also showed a signifi-
cant association (log-rank P  .00048), which is in strong linkage
disequilibrium (LD) with rs3740065 (r2 of LD 0.79). No signif-
icant associations between genotypes and recurrence-free survival
were observed for the remaining SNPs. Cox proportional hazards
analysis revealed that rs3740065 in ABCC2 was an independent
indicator of recurrence-free survival (trend P  .00017, Table 3)
and that the adjusted HR for patients carrying rs3740065 AA,
compared with patients carrying GG genotype as a reference, was
10.64 (95%CI, 1.44 to 78.88; Table 3), indicating rs3740065A to be
a risk allele of recurrence.
We then investigated a combined effect of CYP2D6 and ABCC2
genotypes on the recurrence-free survival by classifying the patients
into five groups (zero, one, two, three, and four risk allele groups)
according to the number of risk alleles ofCYP2D6 andABCC2 genes.
Kaplan-Meier analysis revealed the number of risk alleles of these two
genes to have cumulative effects on recurrence-free survival (log-rank
P .000000083,Fig2).AdjustedHRs for riskof recurrence computed
for patients carrying two ormore risk alleles increased from 4.93-fold
(two risk alleles) to 45.25-fold (four risk alleles; trendP .000000055,
Table 3).
Associations Between Genotypes and
Plasma Concentrations
To analyze the effects of CYP2D6 and ABCC2 genotypes on the
plasma concentrations of tamoxifen and its metabolites, we recruited
98 independent patients with breast cancer taking tamoxifen 20mg/d
as an adjuvant therapy. The steady-state plasma concentrations of
endoxifen among the three genotypic groups ofwt/wt,wt/V, andV/V
were significantly different (P  .0000043, Fig 3A). Median plasma
concentrations of endoxifen in patients withV/V andwt/Vwere 15.5
and 27.2 ng/mL, respectively, which were 43.8% and 76.8% of the
concentration in patients withwt/wt (35.4 ng/mL). The differences in
plasma 4-hydroxytamoxifen concentrations among CYP2D6 geno-
type groups were also statistically significant (P  .00052, Fig 3C).
When compared among three genotype groups for CYP2D6*10,
similar results were observed (Appendix Fig A1, online only).
However, there was no significant association between genotypes of
ABCC2 rs3740065 and plasma concentrations of endoxifen and
4-hydroxytamoxifen (Figs 3B and 3D). Plasma tamoxifen and
N-desmethyltamoxifen levels were also not significantly different
among the three genotype groups (data not shown).
DISCUSSION
Adjuvant tamoxifen treatment substantially improves the10-year sur-
vival of patients with ER-positive breast cancer, with a significant
Table 2. Genotype Frequency of CYP2D6
Combined CYP2D6 genotype† No. of Patients %
wt/wt
*1/*1 83 29.4
wt/V
*1/*4 1 0.4
*1/*5 17 6.0
*1/*10 105 37.2
*1/*10-*10 3 1.1
*1/*14 1 0.4
*1/*21 2 0.7
*1/*36-*36 1 0.4
*1/*41 5 1.8
*1-*1/*10 1 0.4
V/V
*5/*5 1 0.4
*5/*10 9 3.2
*5/*21 1 0.4
*5/*41 2 0.7
*10/*10 45 16.0
*10/*10-*10 1 0.4
*10/*21 1 0.4
*10/*36-*36 2 0.7
*10/*41 1 0.4
†All decreased or null alleles (*4, *5, *10, *10-*10, *14, *21, *36-*36, and *41)
were defined as an allele V, and *1 and *1-*1 alleles were defined as wt.
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Fig 1. Kaplan-Meier estimates of recurrence-free survival for CYP2D6 and ABCC2 rs3740065 genotypes. (A) Comparison of 282 patients with wt/wt, wt/V, and V/V
of CYP2D6. (B) Comparison of 282 patients with AA, AG, and GG genotypes at rs3740065 in ABCC2.
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reduction in breast cancer recurrence and mortality.2 Although aro-
matase inhibitors have demonstrated superiority to tamoxifen as ad-
juvant therapy for early breast cancer in postmenopausal women,
there are some reports indicating that aromatase inhibitors are asso-
ciated with a higher risk of osteoporosis than tamoxifen.25,26 There-
fore, tamoxifen still plays a major therapeutic role in ER-positive
breast cancer. We previously reported that CYP2D6*10 was signifi-
cantly associated with clinical outcome in 67 patients with breast
cancer receiving adjuvant tamoxifen monotherapy.7 One group rep-
licated this association; they also found a significant association be-
tween CYP2D6*10 and disease-free survival in 152 patients.27 Lim et
al28 reportedasignificantassociationbetweenCYP2D6*10andtimeto
progression for patients with metastatic breast cancer receiving ta-
moxifen, which supports our results. We studied additional patients
with breast cancer who received tamoxifen monotherapy and con-
firmed the significant associations ofCYP2D6*10with recurrence-
free survival in the additionally collected sample set (n  175;
log-rank P .0048). When sample sets of the previous and current
studies were combined, the patients with CYP2D6*1/*10 and
CYP2D6*10/*10 showed significantly shorter recurrence-free survival
compared with patients with CYP2D6*1/*1 (log-rank P  .00027,
Appendix Fig A1). We also clarified that CYP2D6*10 was associated
with lower plasma levels of endoxifen using 98 patients with breast
cancer who were receiving tamoxifen therapy (Appendix Fig A1).
These results suggest that a lower clinical efficacy in the tamoxifen-
treated patients with CYP2D6*10/*10 may be caused by lower sys-
temic exposure to endoxifen.
We found that two SNPs inABCC2were significantly associated
with recurrence-free survival of the patients receiving tamoxifen
monotherapy. ABCC2 is a member of the ABC transporter, which is
involved in the transport of many kinds of drugs and glucuronide
conjugates. An in vitro study reporting that ABCC2 was expressed at
higher levels in tamoxifen-resistant breast cancer cells suggested that
active metabolites of tamoxifen were transported by ABCC2 from
breast cancer cells.29 Although wemeasured steady-state plasma con-
centrations of tamoxifen and itsmetabolites, we could not find signif-
icant differences among the ABCC2 rs3740065 genotype groups (Fig
3). From these lines of evidence, we suspect that ABCC2might regu-
late local exposure of endoxifen to breast cancer cells. The SNPmost
significantly associated with recurrence-free survival (rs3740065) in
this study was one of the tag-SNPs located in intron 29 of theABCC2
gene. Although we also genotyped one nonsynonymous SNP
rs2273697 (I417V),30 we could not find any association of this SNP
with recurrence-free survival (log-rank P  .88, r2 of LD with
rs3740065  0.05). Therefore, we speculate that rs3740065 SNP or
some other genetic variations linked to rs3740065 in ABCC2may be
associated with increased expression levels or transport activity of
ABCC2 in breast cancer tissue, causing the lower exposure of breast
cancer cells to endoxifen. However, further functional analysis will be
needed to clarify the biologic mechanisms associated with clinical
outcome of tamoxifen therapy.
Table 3. Recurrences and Hazard Ratios for Recurrence-Free Survival in Patients With Breast Cancer Treated With Tamoxifen
Variable
No. of
Patients
No. of
Recurrences
Adjusted Hazard
Ratio 95% CI
P
(trend test)
CYP2D6 genotype .000036
wt/wt 84 3 1.00 (reference)
wt/V 135 20 4.44 1.31 to 15.00
V/V 63 18 9.52 2.79 to 32.45
ABCC2 rs3740065 .00017
GG 39 1 1.00 (reference)
AG 131 14 3.52 0.46 to 26.79
AA 112 26 10.64 1.44 to 78.88
No. of risk alleles of CYP2D6 and ABCC2 rs3740065 .000000055
0 13 0
1 52 1 1.00 (reference)†
2 109 8 4.93 0.61 to 39.63
3 86 23 19.98 2.69 to 148.65
4 22 9 45.25 5.58 to 366.81
Adjusted for tumor size and nodal status.
†The reference category included  one risk allele.
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Fig 2. Kaplan-Meier estimates of recurrence-free survival for combination
effects of CYP2D6 and ABCC2 genotypes. The patients were classified into five
groups (zero, one, two, three, or four alleles) based on the number of risk alleles
of these two genes.
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In summary, our results indicate that genetic polymorphisms in
CYP2D6 and ABCC2 may be important predictors for the clinical
outcomeof tamoxifen treatment forpatientswithbreast cancer.These
findingshave thepotential to improve theabilityofphysicians to select
optimal hormonal therapy for the treatment of hormone receptor–
positive breast cancer.
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